The grant, plainly. On October 7, 2025, President and Fellows of Harvard College was issued US12435331B2, covering a cytosine-to-guanine base editor. The CPC tags — C12N 15/102, C12N 9/22 (nucleases), C12N 9/78, plus the C12Y 302/305 enzyme series — describe an editor that makes a precise single-base change, a different mechanism from cutting-based CRISPR.
Why a financing desk reads foundational editing IP: next-generation editing companies are typically built on in-licensed academic IP and burn cash for years before any product. A foundational base-editor grant from a leading lab is the kind of asset a company licenses to anchor its platform — and the asset investors are funding the burn to develop.
The cautionary read: foundational IP raises the platform ceiling but comes with license obligations and a long, dilutive development path. Milestone and royalty terms flowing back to the institution are a real claim on future proceeds, and runway is still cash divided by burn. The holder's question is whether each raise buys enough quarters to reach clinical inflection.
What the grant does not show: which company licensed it, on what terms, or with what runway. Those are in corporate filings and the license agreement. The grant establishes the foundational base-editing asset and its scope.
The takeaway: treat foundational base-editor grants as the platform collateral behind next-generation editing raises, then price the license obligations and run the runway math from the filings. Harvard's October 2025 C-to-G editor grant is a dated example of that foundational IP.